In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.
Kristine Slam, MD, FACP, Central Ohio Surgical Associates, spoke at our recent Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14. Here she discusses the positive impact that Choosing Wisely and enhanced recovery after surgery (EROS) protocols have had on patients receiving treatment for breast cancer.
Transcript
What measurable benefits have been observed from the shift to value-based care for breast cancer?
Two of the things that come most to my mind are the Choosing Wisely campaign and EROS protocols.
Choosing Wisely actually started back in 2012, and it was a bunch of societies coming together for mostly patient but also physician education about practices that have been routine for years that actually don't provide that much value to the patient. In the breast cancer world, this actually started by us surgeons not doing unnecessary axillary dissections [or] ordering unnecessary tumor markers. Now it has evolved into, again, ongoing education about not doing routine MRIs, not routinely doing sentinel lymph node biopsies in elderly or low-risk patients, not routinely reexcising lumpectomy close margins. So Choosing Wisely has, again, eliminated both short-term and long-term side effects for patients and financial toxicity.
The second thing that is helpful is something called EROS protocols, and these are specific to surgery. What the EROS protocols are designed for is limiting length of time in the hospital, limiting side effects, and it's through standardization of surgical practices. A lot of this involves preoperative education of patients, but it also is, again, very evidence based about things that work perioperatively to limit patient problems.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More